Pediatric rheumatology

The Janus kinase inhibitor baricitinib has the potential to be “an important part of the treatment landscape” for juvenile arthritis, research suggests.

Male sex and older age may put people with childhood-onset systemic lupus erythematosus and nephritis at increased risk for abnormal short-term kidney status, US researchers report.

Overweight and obesity during childhood may be associated with an increased risk for systemic lupus erythematosus and psoriatic arthritis that persists even if a healthy bodyweight is achieved during adulthood, researchers report.

Findings from three studies provide further support for the effectiveness and safety of COVID-19 vaccines in young people with rheumatic and musculoskeletal diseases.

Infliximab appears efficacious for patients with juvenile-onset spondyloarthritis who have failed to respond to conventional treatment, phase 3 study findings show.

Click through for more details on the EULAR recommendations

Click through for further information on this expanded indication

Click through for more information

Click through for further details on this announcement

The incidence and clinical features of multisystem inflammatory syndrome in children were similar during the delta wave of COVID-19 to those observed during the first year of the pandemic among unvaccinated children and adolescents, Danish research suggests.

Individuals with juvenile idiopathic arthritis have a higher-than-average incidence of celiac disease that may be associated with a family history of autoimmunity and a more severe disease course, Italian researchers report.

Autoantibodies against IL-1Ra are present in a large proportion of patients with MIS-C, say researchers.

Withdrawing therapy on the basis of low levels of high-sensitivity C-reactive protein and the calcium-binding protein S100A12 may be a feasible approach for young people with juvenile idiopathic arthritis in remission, PREVENT-JIA study data show.

Click through for additional details